Bicycle Therapeutics (FRA:50BA) Short Percentage of Float


FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.36
GF Value €12.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:50BA vs ABEO, DMAC, FATE: Short Percentage of Float Comparison

For the Biotechnology subindustry, Bicycle Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Short Percentage of Float falls into.


FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.36 is trading 72.9% below its estimated GF Value™ of €12.39. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • Short Percentage of Float:
  • GF Value™: €12.39 vs. price of €3.36 (72.9% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.36
Price
€12.39
GF Value